Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer (Q38971333)

8 September 2017

title

Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer (English)

1 reference

8 September 2017

1 reference

1 reference

1 reference

12

L Zitvogel

0 references

Guido Kroemer

13

G Kroemer

0 references

Laura Senovilla

14

L Senovilla

0 references

Oliver Kepp

7

O Kepp

0 references

David P Enot

9

D Enot

1 reference

8 September 2017

F Aranda

1

0 references

Mikael Pittet

11

M Pittet

1 reference

8 September 2017

N Bloy

2

1 reference

8 September 2017

J Pesquet

3

1 reference

8 September 2017

B Petit

4

1 reference

8 September 2017

K Chaba

5

1 reference

8 September 2017

A Sauvat

6

1 reference

8 September 2017

N Khadra

8

1 reference

8 September 2017

C Pfirschke

10

1 reference

8 September 2017

language of work or name

English

0 references

publication date

28 July 2014

1 reference

8 September 2017

1 reference

8 September 2017

volume

34

1 reference

8 September 2017

issue

23

1 reference

8 September 2017

page(s)

3053-3062

1 reference

Cisplatin (cis-diamminedichloroplatinum II)

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Recent developments in the field of anticancer platinum complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

The resurgence of platinum-based cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Molecular mechanisms of cisplatin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Testicular germ cell tumors: pathogenesis, diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Medical treatment of advanced testicular cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Mutagenic and carcinogenic properties of platinum-based anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Cisplatin: mode of cytotoxic action and molecular basis of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Contribution of the immune system to the chemotherapeutic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

An immunosurveillance mechanism controls cancer cell ploidy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Immunogenic death of colon cancer cells treated with oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Murine models to evaluate novel and conventional therapeutic strategies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Immune parameters affecting the efficacy of chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

The secret ally: immunostimulation by anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Vitamin B6 metabolism influences the intracellular accumulation of cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Quantitation of mitochondrial alterations associated with apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Chemotherapy induces ATP release from tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Programmed cell removal: a new obstacle in the road to developing cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.234

Biologic characterization of the subcutaneously implanted Lewis lung tumor

31 March 2020

1 reference

12 December 2020

β-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas

1 reference

12 December 2020

Cisplatin resistance: preclinical findings and clinical implications

1 reference

12 December 2020

Mode of DNA binding of cis-platinum(II) antitumor drugs: a base sequence-dependent mechanism is proposed

1 reference

12 December 2020

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/ONC.2014.234

1 reference

Dimensions Publication ID

8 September 2017

1033582392

0 references

1 reference